Kidney dialysis patients: new study tests blood thinner safety
NCT ID NCT04006093
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how a single 5 mg dose of the blood thinner apixaban is processed in people with end-stage kidney disease who are on peritoneal dialysis, compared to people with normal kidney function. Researchers measured drug levels in the blood over time. The goal is to understand if dosing adjustments are needed for this group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- apixaban (a blood thinner)
- What this could lead to
- If successful, this could help doctors determine safe and effective dosing of apixaban for people on peritoneal dialysis.
- What could go wrong
- This is a small, early-phase study with only 24 participants, so results may not apply to everyone. It looks at drug levels, not clinical outcomes like bleeding or clotting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC RENAL INSUFFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Caen
Caen, 14000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug work safely in patients with kidney failure?
- What does life feel like for children with a rare birth defect? a new study asks
- AI therapy coach aims to ease distress in seriously ill seniors
- A simple stretch during dialysis might soothe restless legs
- A regenerative graft could rethink dialysis access
- Pumpkin seed oil may fight inflammation in kidney patients — a trial puts it to the test